Lessons from cancer immunoediting in cutaneous melanoma

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Aris, Mariana ^a,b   Barrio, María Marcela ^b   Mordoh, José ^a,b  

^a FUNDACIÓN INSTITUTO LELOIR   (Argentina)

^b INSTITUTO ALEXANDER FLEMING   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; TUMOR ANTIGEN VACCINE; UNCLASSIFIED DRUG;

CANCER IMMUNOEDITING; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER STEM CELL; CELL HETEROGENEITY; CUTANEOUS MELANOMA; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFLAMMATION; MACROPHAGE; MOLECULAR MECHANICS; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR CELL; TUMOR GROWTH; ANIMAL; DISEASE COURSE; DISEASE MODEL; IMMUNOLOGY; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; MELANOMA; MOUSE; PATHOLOGY; SKIN TUMOR; TUMOR ESCAPE;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; MELANOMA; MICE; SKIN NEOPLASMS; TUMOR ESCAPE;

EID: 84866111138     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/192719     Document Type: Review

References (135)

1. Hanahan D., Weinberg R. A., Hallmarks of cancer: the next generation. Cell 2011 144 5 646 674 2-s2.0-79952284127 10.1016/j.cell.2011.02.013
2. Schreiber R. D., Old L. J., Smyth M. J., Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011 331 6024 1565 1570 2-s2.0-79953151458 10.1126/science.1203486
3. Stutman O., Tumor development after 3 methylcholanthrene in immunologically deficient athymic nude mice. Science 1974 183 4124 534 536 2-s2.0-0015977440
4. Dunn G. P., Bruce A. T., Ikeda H., Old L. J., Schreiber R. D., Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology 2002 3 11 991 998 2-s2.0-0036852241 10.1038/ni1102-991 (Pubitemid 35363648)
5. Kaplan D. H., Shankaran V., Dighe A. S., Stockert E., Aguet M., Old L. J., Schreiber R. D., Demonstration of an interferon γ -dependent tumor surveillance system in immunocompetent mice. Proceedings of the National Academy of Sciences of the United States of America 1998 95 13 7556 7561 2-s2.0-0032560475 10.1073/pnas.95.13.7556 (Pubitemid 28293291)
6. Smyth M. J., Thia K. Y., Street S. E., MacGregor D., Godfrey D. I., Trapani J. A., Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. Journal of Experimental Medicine 2000 192 5 755 760 2-s2.0-0034605122 10.1084/jem.192.5.755
7. Smyth M. J., Thia K. Y., Street S. E., Cretney E., Trapani J. A., Taniguchi M., Kawano T., Pelikan S. B., Crowe N. Y., Godfrey D. I., Differential tumor surveillance by natural killer (NK) and NKT cells. Journal of Experimental Medicine 2000 191 4 661 668 2-s2.0-0034695880 10.1084/jem.191.4.661
8. Shankaran V., Ikeda H., Bruce A. T., White J. M., Swanson P. E., Old L. J., Schreiber R. D., IFN γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001 410 6832 1107 1111 2-s2.0-0035953308 10.1038/35074122 (Pubitemid 32391043)
9. Vesely M. D., Kershaw M. H., Schreiber R. D., Smyth M. J., Natural innate and adaptive immunity to cancer. Annual Review of Immunology 2011 29 235 271 2-s2.0-79953059789 10.1146/annurev-immunol-031210-101324
10. Street S. E., Cretney E., Smyth M. J., Perforin and interferon- γ activities independently control tumor initiation, growth, and metastasis. Blood 2001 97 1 192 197 2-s2.0-0035165729 10.1182/blood.V97.1.192 (Pubitemid 32061260)
11. Dunn G. P., Bruce A. T., Sheehan K. C., Shankaran V., Uppaluri R., Bui J. D., Diamond M. S., Koebel C. M., Arthur C., White J. M., Schreiber R. D., A critical function for type I interferons in cancer immunoediting. Nature Immunology 2005 6 7 722 729 2-s2.0-22144465860 10.1038/ni1213 (Pubitemid 41716746)
12. Sims G. P., Rowe D. C., Rietdijk S. T., Herbst R., Coyle A. J., HMGB1 and RAGE in inflammation and cancer. Annual Review of Immunology 2010 28 367 388 2-s2.0-77952298772 10.1146/annurev.immunol.021908.132603
13. Old L. J., Boyse E. A., Immunology of experimental tumors. Annual Review of Medicine 1964 15 167 186 2-s2.0-0000834072
14. Eyles J., Puaux A. L., Wang X., Toh B., Prakash C., Hong M., Tan T. G., Zheng L., Ong L. C., Jin Y., Kato M., Prévost-Blondel A., Chow P., Yang H., Abastado J. P., Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. The Journal of Clinical Investigation 2010 120 6 2030 2039 2-s2.0-77953225810 10.1172/JCI42002
15. Koebel C. M., Vermi W., Swann J. B., Zerafa N., Rodig S. J., Old L. J., Smyth M. J., Schreiber R. D., Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007 450 7171 903 907 2-s2.0-36849010167 10.1038/nature06309 (Pubitemid 350231320)
16. Naumov G. N., MacDonald I. C., Chambers A. F., Groom A. C., Solitary cancer cells as a possible source of tumour dormancy? Seminars in Cancer Biology 2001 11 4 271 276 2-s2.0-0034860222 10.1006/scbi.2001.0382 (Pubitemid 32799904)
17. Holmgren L., O'Reilly M. S., Folkman J., Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Medicine 1995 1 2 149 153 2-s2.0-0028951043
18. Siegel R., Ward E., Brawley O., Jemal A., The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CAA Cancer Journal for Clinicians 2011 61 212 236
19. Clark W. H. Jr., Elder D. E., Guerry Dt, Braitman L. E., Trock B. J., Schultz D., Synnestvedt M., Halpern A. C., Model predicting survival in stage I melanoma based on tumor progression. Journal of the National Cancer Institute 1989 81 24 1893 1904 2-s2.0-0024814687 (Pubitemid 20026075)
20. Edge S. B., Compton C. C., The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Annals of Surgical Oncology 2010 17 6 1471 1474 2-s2.0-77954818058 10.1245/s10434-010- 0985-4
21. Coulie P. G., Brichard V., Van Pel A., Wölfel T., Schneider J., Traversari C., Mattei S., De Plaen E., Lurquin C., Szikora J. P., Renauld J. C., Boon T., A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. Journal of Experimental Medicine 1994 180 1 35 42 2-s2.0-0028303166 10.1084/jem.180.1.35 (Pubitemid 24181053)
22. Kawakami Y., Eliyahu S., Delgado C. H., Robbins P. F., Rivoltini L., Topalian S. L., Miki T., Rosenberg S. A., Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proceedings of the National Academy of Sciences of the United States of America 1994 91 9 3515 3519 2-s2.0-0028316911 (Pubitemid 24139460)
23. Kawakami Y., Eliyahu S., Delgado C. H., Robbins P. F., Sakaguchi K., Appella E., Yannelli J. R., Adema G. J., Miki T., Rosenberg S. A., Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proceedings of the National Academy of Sciences of the United States of America 1994 91 14 6458 6462 2-s2.0-0028298174 10.1073/pnas.91.14.6458 (Pubitemid 24200680)
24. Brichard V., Van Pel A., Wolfel T., Wolfel C., De Plaen E., Lethe B., Coulie P., Boon T., The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. Journal of Experimental Medicine 1993 178 2 489 495 2-s2.0-0027165558 (Pubitemid 23218197)
25. Cohan T., Muller R. M., Tomita Y., Shibahara S., Nucleotide sequence of the cDNA encoding human tyrosinase-related protein. Nucleic Acids Research 1990 18 9 2807 2808 2-s2.0-0025305063 (Pubitemid 20150633)
26. Wang R. F., Appella E., Kawakami Y., Kang X., Rosenberg S. A., Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. Journal of Experimental Medicine 1996 184 6 2207 2216 2-s2.0-0030472678 10.1084/jem.184.6.2207 (Pubitemid 27023721)
27. Godet Y., Moreau-Aubry A., Guilloux Y., Vignard V., Khammari A., Dreno B., Jotereau F., Labarriere N., MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. Journal of Experimental Medicine 2008 205 11 2673 2682 2-s2.0-58149153043 10.1084/jem.20081356
28. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van Den Eynde B., Knuth A., Boon T., A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991 254 5038 1643 1647 2-s2.0-0026322151 (Pubitemid 21917508)
29. Chen Y. T., Scanlan M. J., Sahin U., Türeci Ö.., Gure A. O., Tsang S., Williamson B., Stockert E., Pfreundschuh M., Old L. J., A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proceedings of the National Academy of Sciences of the United States of America 1997 94 5 1914 1918 2-s2.0-12644276375 10.1073/pnas.94.5.1914 (Pubitemid 27113936)
30. Davies H., Bignell G. R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M. J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B. A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G. J., Bigner D. D., Palmleri G., Cossu A., Flanagan A., Nicholson A., Ho J. W. C., Leung S. Y., Yuen S. T., Weber B. L., Seigler H. F., Darrow T. L., Paterson H., Marais R., Marshall C. J., Wooster R., Stratton M. R., Futreal P. A., Mutations of the BRAF gene in human cancer. Nature 2002 417 6892 949 954 2-s2.0-18444374405 10.1038/nature00766 (Pubitemid 34716871)
31. Kalialis L. V., Drzewiecki K. T., Klyver H., Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Research 2009 19 5 275 282 2-s2.0-73349134996 10.1097/CMR.0b013e32832eabd5
32. Clemente C. G., Mihm M. C. Jr., Bufalino R., Zurrida S., Collini P., Cascinelli N., Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996 77 7 1303 1310 (Pubitemid 26102328)
33. van Houdt I. S., Sluijter B. J., Moesbergen L. M., Vos W. M., de Gruijl T. D., Molenkamp B. G., Van Den Eertwegh A. J. M., Hooijberg E., Van Leeuwen P. A. M., Meijer C. J. L. M., Oudejans J. J., Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. International Journal of Cancer 2008 123 3 609 615 2-s2.0-46049103179 10.1002/ijc.23543 (Pubitemid 351898419)
34. Yuan J., Page D. B., Ku G. Y., Li Y., Mu Z., Ariyan C., Gallardo H. F., Roman R. A., Heine A. I., Terzulli S. L., Gnjatic S., Ritter G., Jungbluth A. A., Allison J. P., Old L. J., Wolchok J. D., Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immunity 2010 10, article 1 2-s2.0-77449105831
35. Yamshchikov G. V., Mullins D. W., Chang C. C., Ogino T., Thompson L., Presley J., Galavotti H., Aquila W., Deacon D., Ross W., Patterson J. W., Engelhard V. H., Ferrone S., Slingluff C. L., Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. Journal of Immunology 2005 174 11 6863 6871 2-s2.0-21044437815 (Pubitemid 40705650)
36. Frisch M., Biggar R. J., Engels E. A., Goedert J. J., Association of cancer with AIDS-related immunosuppression in adults. Journal of the American Medical Association 2001 285 13 1736 1745 2-s2.0-0035804852 (Pubitemid 32259908)
37. Vajdic C. M., McDonald S. P., McCredie M. R., van Leeuwen M. T., Stewart J. H., Law M., Chapman J. R., Webster A. C., Kaldor J. M., Grulich A. E., Cancer incidence before and after kidney transplantation. Journal of the American Medical Association 2006 296 23 2823 2831 2-s2.0-33845711356 10.1001/jama.296.23.2823 (Pubitemid 44969182)
38. MacKie R. M., Reid R., Junor B., Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. The New England Journal of Medicine 2003 348 6 567 568 2-s2.0-0037421593 10.1056/NEJM200302063480620 (Pubitemid 36159900)
39. Polak M. E., Borthwick N. J., Gabriel F. G., Johnson P., Higgins B., Hurren J., McCormick D., Jager M. J., Cree I. A., Mechanisms of local immunosuppression in cutaneous melanoma. British Journal of Cancer 2007 96 12 1879 1887 2-s2.0-34250360586 10.1038/sj.bjc.6603763 (Pubitemid 46912012)
40. Shields J. D., Kourtis I. C., Tomei A. A., Roberts J. M., Swartz M. A., Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 2010 328 5979 749 752 2-s2.0-77952231121 10.1126/science.1185837
41. Mourmouras V., Fimiani M., Rubegni P., Epistolato M. C., Malagnino V., Cardone C., Cosci E., Nisi M. C. D., Miracco C., Evaluation of tumour-infiltrating CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases. British Journal of Dermatology 2007 157 3 531 539 2-s2.0-34547896612 10.1111/j.1365-2133.2007. 08057.x (Pubitemid 47256132)
42. Speeckaert R., Vermaelen K., van Geel N., Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. European Journal of Cancer. In press
43. Vence L., Palucka A. K., Fay J. W., Ito T., Liu Y. J., Banchereau J., Ueno H., Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proceedings of the National Academy of Sciences of the United States of America 2007 104 52 20884 20889 2-s2.0-38049129212 10.1073/pnas.0710557105
44. Jensen T. O., Schmidt H., Moller H. J., Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 2012 118 9 2476 2485
45. Gerlini G., Urso C., Mariotti G., Di Gennaro P., Palli D., Brandani P., Salvadori A., Pimpinelli N., Reali U. M., Borgognoni L., Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clinical Immunology 2007 125 2 184 193 2-s2.0-35248847969 10.1016/j.clim.2007.07.018 (Pubitemid 47562900)
46. Gerlini G., Di Gennaro P., Mariotti G., Urso C., Chiarugi A., Pimpinelli N., Borgognoni L., Indoleamine 2,3-dioxygenase cells correspond to the BDCA2 plasmacytoid dendritic cells in human melanoma sentinel nodes. Journal of Investigative Dermatology 2010 130 3 898 901 2-s2.0-76649114336 10.1038/jid.2009.307
47. Konjević G., Miräjaić Martinovi K., Jurišić V., Babović N., Spužić I., Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: decreased NKG2D and increased CD158a receptors on CD3-CD16+ NK cells. Biomarkers 2009 14 4 258 270 2-s2.0-68549125484 10.1080/13547500902814658
48. Mirjacic Martinovic K., Konjevic G., Babovic N., Inic M., The stage dependent changes in NK cell activity and the expression of activating and inhibitory NK cell receptors in melanoma patients. Journal of Surgical Research 2011 171 2 637 649
49. Zippelius A., Batard P., Rubio-Godoy V., Bioley G., Liénard D., Lejeune F., Rimoldi D., Guillaume P., Meidenbauer N., Mackensen A., Rufer N., Lubenow N., Speiser D., Cerottini J. C., Romero P., Pittet M. J., Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Research 2004 64 8 2865 2873 2-s2.0-4344671644 10.1158/0008-5472.CAN-03-3066 (Pubitemid 38500627)
50. Pepe C. A., Ricci R., Cortelazzi C., Mori G., Zambito F., Campanini N., Aimi F., Santoro S., Lombardi M., Santini M., de Panfilis G., The vast majority of lymphocytes infiltrating primary cutaneous melanoma express the CD27 costimulatory receptor: implications for melanoma progression. European Journal of Dermatology 2011 21 2 178 183 2-s2.0-79960802139 10.1684/ejd.2010.1240
51. Zubieta M. R., Furman D., Barrio M., Bravo A. I., Domenichini E., Mordoh J., Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. American Journal of Pathology 2006 168 5 1666 1675 2-s2.0-33646509028 10.2353/ajpath.2006.050971
52. Radosavljevic G., Jovanovic I., Majstorovic I., Mitrovic M., Lisnic V. J., Arsenijevic N., Jonjic S., Lukic M. L., Deletion of galectin-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activity. Clinical and Experimental Metastasis 2011 28 5 451 462 2-s2.0-79955523647 10.1007/s10585-011-9383-y
53. Grivennikov S. I., Greten F. R., Karin M., Immunity, inflammation, and cancer. Cell 2010 140 6 883 899 2-s2.0-77950346282 10.1016/j.cell.2010.01.025
54. Kanavy H. E., Gerstenblith M. R., Ultraviolet radiation and melanoma. Seminars in Cutaneous Medicine and Surgery 2011 30 222 228
55. Grivennikov S. I., Karin M., Dangerous liaisons: STAT3 and NF- κ B collaboration and crosstalk in cancer. Cytokine and Growth Factor Reviews 2010 21 1 11 19 2-s2.0-77549083560 10.1016/j.cytogfr.2009.11.005
56. Sica A., Allavena P., Mantovani A., Cancer related inflammation: the macrophage connection. Cancer Letters 2008 267 2 204 215 2-s2.0-47749155653 10.1016/j.canlet.2008.03.028
57. Gazzaniga S., Bravo A. I., Guglielmotti A., Van Rooijen N., Maschi F., Vecchi A., Mantovani A., Mordoh J., Wainstok R., Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. Journal of Investigative Dermatology 2007 127 8 2031 2041 2-s2.0-34447556692 10.1038/sj.jid.5700827 (Pubitemid 47075380)
58. Chen P., Huang Y., Bong R., Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner. Clinical Cancer Research 2011 17 23 7230 7239
59. Bianchini F., Massi D., Marconi C., Franchi A., Baroni G., Santucci M., Mannini A., Mugnai G., Calorini L., Expression of cyclo-oxygenase-2 in macrophages associated with cutaneous melanoma at different stages of progression. Prostaglandins and Other Lipid Mediators 2007 83 4 320 328 2-s2.0-34248171189 10.1016/j.prostaglandins.2007.03.003 (Pubitemid 46710469)
60. Fujimura T., Ring S., Umansky V., Mahnke K., Enk A. H., Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas. Journal of Investigative Dermatology 2012 132 4 1239 1246
61. Meyer C., Sevko A., Ramacher M., Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proceedings of the National Academy of Sciences of the United States of America 2011 108 41 17111 17116
62. Toh B., Wang X., Keeble J., Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biology 2011 9 9 e1001162 10.1371/journal.pbio.1001162
63. Poschke I., Mougiakakos D., Hansson J., Masucci G. V., Kiessling R., Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Research 2010 70 11 4335 4345 2-s2.0-77953141534 10.1158/0008-5472.CAN-09-3767
64. Slattery M. J., Dong C., Neutrophils influence melanoma adhesion and migration under flow conditions. International Journal of Cancer 2003 106 5 713 722 2-s2.0-0042023405 10.1002/ijc.11297 (Pubitemid 36993395)
65. Schmidt H., Suciu S., Punt C. J., Gore M., Kruit W., Patel P., Lienard D., Von Der Maase H., Eggermont A. M. M., Keilholz U., Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 biochemotherapy trial. Journal of Clinical Oncology 2007 25 12 1562 1569 2-s2.0-34248218014 10.1200/JCO.2006.09.0274 (Pubitemid 46733083)
66. Artuc M., Guhl S., Babina M., Mast cell-derived TNF-alpha and histamine modify IL-6 and IL-8 expression and release from cutaneous tumor cells. Experimental Dermatology 2011 20 1020 1022
67. Toth-Jakatics R., Jimi S., Takebayashi S., Kawamoto N., Cutaneous malignant melanoma: correlation between neovascularization and peritumor accumulation of mast cells overexpressing vascular endothelial growth factor. Human Pathology 2000 31 8 955 960 2-s2.0-0033850853 10.1053/hupa.2000.16658
68. Ribatti D., Ennas M. G., Vacca A., Ferreli F., Nico B., Orru S., Sirigu P., Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. European Journal of Clinical Investigation 2003 33 5 420 425 2-s2.0-0037569416 10.1046/j.1365-2362.2003.01152.x (Pubitemid 36583711)
69. Kirkwood J. M., Manola J., Ibrahim J., Sondak V., Ernstoff M. S., Rao U., A pooled analysis of Eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clinical Cancer Research 2004 10 5 1670 1677 2-s2.0-1842533233 10.1158/1078-0432.CCR-1103-3 (Pubitemid 38435557)
70. Tarhini A. A., Kirkwood J. M., Gooding W. E., Cai C., Agarwala S. S., Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. Journal of Clinical Oncology 2007 25 25 3802 3807 2-s2.0-34548543781 10.1200/JCO.2006.10.2822 (Pubitemid 47477253)
71. Maeurer M. J., Gollin S. M., Martin D., Swaney W., Bryant J., Castelli C., Robbins P., Parmiani G., Storkus W. J., Lotze M. T., Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. The Journal of Clinical Investigation 1996 98 7 1633 1641 2-s2.0-10144223555 (Pubitemid 26327874)
72. Chapman P. B., Hauschild A., Robert C., Haanen J. B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., Hogg D., Lorigan P., Lebbe C., Jouary T., Schadendorf D., Ribas A., O'Day S. J., Sosman J. A., Kirkwood J. M., Eggermont A. M. M., Dreno B., Nolop K., Li J., Nelson B., Hou J., Lee R. J., Flaherty K. T., McArthur G. A., Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England Journal of Medicine 2011 364 26 2507 2516 2-s2.0-79959795786 10.1056/NEJMoa1103782
73. Comin-Anduix B., Chodon T., Sazegar H., Matsunaga D., Mock S., Jalil J., Escuin-Ordinas H., Chmielowski B., Koya R. C., Ribas A., The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clinical Cancer Research 2010 16 24 6040 6048 2-s2.0-78650391890 10.1158/1078-0432.CCR-10-1911
74. Wilmott J. S., Long G. V., Howle J. R., Selective BRAF inhibitors induce marked T cell infiltration into human metastatic melanoma. Clinical Cancer Research 2012 18 5 1386 1394
75. Rakhra K., Bachireddy P., Zabuawala T., Zeiser R., Xu L., Kopelman A., Fan A. C., Yang Q., Braunstein L., Crosby E., Ryeom S., Felsher D. W., CD4+ T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 2010 18 5 485 498 2-s2.0-78249257291 10.1016/j.ccr.2010.10.002
76. Khong H. T., Rosenberg S. A., Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy. Journal of Immunology 2002 168 2 951 956 2-s2.0-0037080226 (Pubitemid 34049600)
77. Germeau C., Ma W., Schiavetti F., Lurquin C., Henry E., Vigneron N., Brasseur F., Lethé B., De Plaen E., Velu T., Boon T., Coulie P. G., High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. Journal of Experimental Medicine 2005 201 2 241 248 2-s2.0-19944434269 10.1084/jem.20041379 (Pubitemid 40189433)
78. Lurquin C., Lethé B., De Plaen E., Corbière V., Théate I., Van Baren N., Coulie P. G., Boon T., Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. Journal of Experimental Medicine 2005 201 2 249 257 2-s2.0-13244273592 10.1084/jem.20041378 (Pubitemid 40189434)
79. Bins A., Mallo H., Sein J., van den Bogaard C., Nooijen W., Vyth-Dreese F., Nuijen B., De Gast G. C., Haanen J. B. A. G., Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A0201-positive melanoma patients. Journal of Immunotherapy 2007 30 2 234 239 2-s2.0-34247620750 10.1097/01.cji.0000211333.06762.47 (Pubitemid 46667803)
80. Hodi F. S., O'Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B., Gonzalez R., Robert C., Schadendorf D., Hassel J. C., Akerley W., Van Den Eertwegh A. J. M., Lutzky J., Lorigan P., Vaubel J. M., Linette G. P., Hogg D., Ottensmeier C. H., Lebbé C., Peschel C., Quirt I., Clark J. I., Wolchok J. D., Weber J. S., Tian J., Yellin M. J., Nichol G. M., Hoos A., Urba W. J., Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine 2010 363 8 711 723 2-s2.0-77954801079 10.1056/NEJMoa1003466
81. Klages K., Mayer C. T., Lahl K., Loddenkemper C., Teng M. W. L., Ngiow S. F., Smyth M. J., Hamann A., Huehn J., Sparwasser T., Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Research 2010 70 20 7788 7799 2-s2.0-78049276260 10.1158/0008-5472.CAN-10-1736
82. Barrio M. M., de Motta P. T., Kaplan J., Von Euw E. M., Bravo A. I., Chacón R. D., Mordoh J., A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients. Journal of Immunotherapy 2006 29 4 444 454 2-s2.0-33747879399 10.1097/01.cji.0000208258.79005.5f (Pubitemid 44288957)
83. von Euw E. M., Barrio M. M., Furman D., Bianchini M., Levy E. M., Yee C., Li Y., Wainstok R., Mordoh J., Monocyte-derived dendritic cells loaded with a mixture of apoptotic/ necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8+ T lymphocytes. Journal of Translational Medicine 2007 5, article 19 2-s2.0-34248172345 10.1186/1479-5876-5-19 (Pubitemid 46722216)
84. von Euw E. M., Barrio M. M., Furman D., Levy E. M., Bianchini M., Peguillet I., Lantz O., Vellice A., Kohan A., Chacón M., Yee C., Wainstok R., Mordoh J., A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10-1082 promoter genotype as predictor of disease progression. Journal of Translational Medicine 2008 6, article 6 2-s2.0-40749136181 10.1186/1479-5876-6-6 (Pubitemid 351384273)
85. Hershkovitz L., Schachter J., Treves A. J., Besser M. J., Focus on adoptive T cell transfer trials in melanoma. Clinical and Developmental Immunology 2010 2010 11 2-s2.0-79952228946 10.1155/2010/260267 260267
86. Dudley M. E., Wunderlich J. R., Yang J. C., Sherry R. M., Topalian S. L., Restifo N. P., Royal R. E., Kammula U., White D. E., Mavroukakis S. A., Rogers L. J., Gracia G. J., Jones S. A., Mangiameli D. P., Pelletier M. M., Gea-Banacloche J., Robinson M. R., Berman D. M., Filie A. C., Abati A., Rosenberg S. A., Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. Journal of Clinical Oncology 2005 23 10 2346 2357 2-s2.0-20244366111 10.1200/JCO.2005.00.240 (Pubitemid 46218728)
87. Dudley M. E., Wunderlich J. R., Robbins P. F., Yang J. C., Hwu P., Schwartzentruber D. J., Topalian S. L., Sherry R., Restifo N. P., Hubicki A. M., Robinson M. R., Raffeld M., Duray P., Seipp C. A., Rogers-Freezer L., Morton K. E., Mavroukakis S. A., White D. E., Rosenberg S. A., Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002 298 5594 850 854 2-s2.0-0037174674 10.1126/science.1076514 (Pubitemid 35231542)
88. Dudley M. E., Yang J. C., Sherry R., Hughes M. S., Royal R., Kammula U., Robbins P. F., Huang J., Citrin D. E., Leitman S. F., Wunderlich J., Restifo N. P., Thomasian A., Downey S. G., Smith F. O., Klapper J., Morton K., Laurencot C., White D. E., Rosenberg S. A., Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. Journal of Clinical Oncology 2008 26 32 5233 5239 2-s2.0-55949125601 10.1200/JCO.2008.16.5449
89. Besser M. J., Shapira-Frommer R., Treves A. J., Zippel D., Itzhaki O., Hershkovitz L., Levy D., Kubi A., Hovav E., Chermoshniuk N., Shalmon B., Hardan I., Catane R., Markel G., Apter S., Ben-Nun A., Kuchuk I., Shimoni A., Nagler A., Schachter J., Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clinical Cancer Research 2010 16 9 2646 2655 2-s2.0-77951714425 10.1158/1078-0432.CCR-10-0041
90. Morgan R. A., Dudley M. E., Wunderlich J. R., Hughes M. S., Yang J. C., Sherry R. M., Royal R. E., Topalían S. L., Kammula U. S., Restifo N. P., Zheng Z., Nahvi A., De Vries C. R., Rogers-Freezer L. J., Mavroukakis S. A., Rosenberg S. A., Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006 314 5796 126 129 2-s2.0-33749624177 10.1126/science.1129003 (Pubitemid 44547756)
91. Johnson L. A., Morgan R. A., Dudley M. E., Cassard L., Yang J. C., Hughes M. S., Kammula U. S., Royal R. E., Sherry R. M., Wunderlich J. R., Lee C. C. R., Restifo N. P., Schwarz S. L., Cogdill A. P., Bishop R. J., Kim H., Brewer C. C., Rudy S. F., VanWaes C., Davis J. L., Mathur A., Ripley R. T., Nathan D. A., Laurencot C. M., Rosenberg S. A., Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009 114 3 535 546 2-s2.0-70149114880 10.1182/blood-2009-03-211714
92. Yee C., Thompson J. A., Byrd D., Riddell S. R., Roche P., Celis E., Greenberg P. D., Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proceedings of the National Academy of Sciences of the United States of America 2002 99 25 16168 16173 2-s2.0-0037058993 10.1073/pnas.242600099 (Pubitemid 35462767)
93. Mackensen A., Meidenbauer N., Vogl S., Laumer M., Berger J., Andreesen R., Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. Journal of Clinical Oncology 2006 24 31 5060 5069 2-s2.0-33750940238 10.1200/JCO.2006.07.1100 (Pubitemid 46631410)
94. Reya T., Morrison S. J., Clarke M. F., Weissman I. L., Stem cells, cancer, and cancer stem cells. Nature 2001 414 6859 105 111 2-s2.0-0035499267 10.1038/35102167 (Pubitemid 33041634)
95. Quintana E., Shackleton M., Foster H. R., Fullen D. R., Sabel M. S., Johnson T. M., Morrison S. J., Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010 18 5 510 523 2-s2.0-78249250559 10.1016/j.ccr.2010. 10.012
96. Boiko A. D., Razorenova O. V., van de Rijn M., Swetter S. M., Johnson D. L., Ly D. P., Butler P. D., Yang G. P., Joshua B., Kaplan M. J., Longaker M. T., Weissman I. L., Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010 466 133 137 2-s2.0-79951792645 10.1038/nature09759
97. Schatton T., Schütte U., Frank N. Y., Zhan Q., Hoerning A., Robles S. C., Zhou J., Hodi F. S., Spagnoli G. C., Murphy G. F., Frank M. H., Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Research 2010 70 2 697 708 2-s2.0-76549126237 10.1158/0008-5472.CAN-09-1592
98. Quintana E., Shackleton M., Sabel M. S., Fullen D. R., Johnson T. M., Morrison S. J., Efficient tumour formation by single human melanoma cells. Nature 2008 456 7222 593 598 2-s2.0-57349143739 10.1038/nature07567
99. Robbins P. F., Dudley M. E., Wunderlich J., El-Gamil M., Li Y. F., Zhou J., Huang J., Powell D. J., Rosenberg S. A., Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. Journal of Immunology 2004 173 12 7125 7130 2-s2.0-10344261422 (Pubitemid 39628146)
100. Rosenberg S. A., Dudley M. E., Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 2004 101 supplement 2 14639 14645 2-s2.0-5144226237 10.1073/pnas.0405730101 (Pubitemid 39346736)
101. Aris M., Zubieta M. R., Colombo M., MART-1- and gp100-expressing and -non-expressing melanoma cells are equally proliferative in tumors and clonogenic in vitro. Journal of Investigative Dermatology 2012 132 365 374 10.1038/jid.2011.312
102. Lozupone F., Rivoltini L., Luciani F., Venditti M., Lugini L., Cova A., Squarcina P., Parmiani G., Belardelli F., Fais S., Adoptive transfer of an anti-MART-127-35-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice. European Journal of Immunology 2003 33 2 556 566 2-s2.0-0344407022 10.1002/immu.200310032 (Pubitemid 36267622)
103. Sanchez-Perez L., Kottke T., Diaz R. M., Ahmed A., Thompson J., Chong H., Melcher A., Holmen S., Daniels G., Vile R. G., Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Research 2005 65 5 2009 2017 2-s2.0-20144387910 10.1158/0008-5472.CAN- 04-3216 (Pubitemid 40478631)
104. Paco L., Garcia-Lora A. M., Casares C., Cabrera C., Algarra I., Collado A., Maleno I., Garrido F., Lopez-Nevot M. A., Total loss of HLA class I expression on a melanoma cell line after growth in nude mice in absence of autologous antitumor immune response. International Journal of Cancer 2007 121 9 2023 2030 2-s2.0-34648834234 10.1002/ijc.22925 (Pubitemid 47463166)
105. Garrido C., Algarra I., Maleno I., Stefanski J., Collado A., Garrido F., Garcia-Lora A. M., Alterations of HLA class i expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity. Cancer Immunology, Immunotherapy 2010 59 1 13 26 2-s2.0-70350107568 10.1007/s00262-009-0716-5
106. Lehmann F., Marchand M., Hainaut P., Pouillart P., Sastre X., Ikeda H.,
107. Jäger E., Ringhoffer M., Karbach J., Arand M., Oesch F., Knuth A., Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. International Journal of Cancer 1996 66 4 470 476 (Pubitemid 26178170)
108. Restifo N. P., Marincola F. M., Kawakami Y., Taubenberger J., Yannelli J. R., Rosenberg S. A., Loss of functional beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. Journal of the National Cancer Institute 1996 88 2 100 108 2-s2.0-0029670776 10.1093/jnci/88.2.100 (Pubitemid 26020098)
109. Jager E., Ringhoffer M., Altmannsberger M., Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. International Journal of Cancer 1997 71 2 142 147 (Pubitemid 27252981)
110. Khong H. T., Wang Q. J., Rosenberg S. A., Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. Journal of Immunotherapy 2004 27 3 184 190 2-s2.0-4143149381 (Pubitemid 39118082)
111. Riteau B., Faure F., Menier C., Viel S., Carosella E. D., Amigorena S., Rouas-Freiss N., Exosomes bearing HLA-G are released by melanoma cells. Human Immunology 2003 64 11 1064 1072 2-s2.0-0242525146 10.1016/j.humimm.2003.08.344 (Pubitemid 37413716)
112. Fuertes M. B., Girart M. V., Molinero L. L., Domaica C. I., Rossi L. E., Barrio M. M., Mordoh J., Rabinovich G. A., Zwirner N. W., Intracellular retention of the NKG2D ligand MHC class i chain-related gene a in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. Journal of Immunology 2008 180 7 4606 4614 2-s2.0-44449119045
113. Derré L., Corvaisier M., Charreau B., Moreau A., Godefroy E., Moreau-Aubry A., Jotereau F., Gervois N., Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. Journal of Immunology 2006 177 5 3100 3107 2-s2.0-33747793367 (Pubitemid 44277827)
114. Brody J. R., Costantino C. L., Berger A. C., Sato T., Lisanti M. P., Yeo C. J., Emmons R. V., Witkiewicz A. K., Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle 2009 8 12 1930 1934 2-s2.0-67649356699
115. Prendergast G. C., Metz R., Muller A. J., IDO recruits tregs in melanoma. Cell Cycle 2009 8 12 1818 1819 2-s2.0-67649327125
116. Martin-Orozco N., Li Y., Wang Y., Liu S., Hwu P., Liu Y. J., Dong C., Radvanyi L., Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Research 2010 70 23 9581 9590 2-s2.0-78649941232 10.1158/0008-5472.CAN-10-1379
117. Itakura E., Huang R. R., Wen D. R., Paul E., Wünsch P. H., Cochran A. J., IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Modern Pathology 2011 24 6 801 809 2-s2.0-79957884105 10.1038/modpathol.2011.5
118. Schoof N., Iles M. M., Bishop D. T., Newton-Bishop J. A., Barrett J. H., Consortium GenoMEL, Pathway-based analysis of a melanoma genome-wide association study: analysis of genes related to tumour-immunosuppression. PLoS ONE 2011 6 12 e29451
119. Hahne M., Rimoldi D., Schröter M., Romero P., Schreier M., French L. E., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J. C., Tschopp J., Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996 274 5291 1363 1366 2-s2.0-10544232277 10.1126/science.274.5291.1363 (Pubitemid 26391458)
120. Dong H., Strome S. E., Salomao D. R., Tamura H., Hirano F., Flies D. B., Roche P. C., Lu J., Zhu G., Tamada K., Lennon V. A., Celis E., Chen L., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Medicine 2002 8, article 1039 793 800 2-s2.0-18544363923 10.1038/nm0902-1039a
121. Andreola G., Rivoltini L., Castelli C., Huber V., Perego P., Deho P., Squarcina P., Accornero P., Lozupone F., Lugini L., Stringaro A., Molinari A., Arancia G., Gentile M., Parmiani G., Fais S., Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. Journal of Experimental Medicine 2002 195 10 1303 1316 2-s2.0-0037141153 10.1084/jem.20011624 (Pubitemid 34564332)
122. Martínez-Lorenzo M. J., Anel A., Alava M. A., Piñeiro A., Naval J., Lasierra P., Larrad L., The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack. Experimental Cell Research 2004 295 2 315 329 2-s2.0-1842850783 10.1016/j.yexcr.2003.12.024 (Pubitemid 38490488)
123. Brown E. R., Doig T., Anderson N., Association of galectin-3 expression with melanoma progression and prognosis. European Journal of Cancer 2012 48 6 865 874 10.1016/j.ejca.2011.09.003
124. Lesport E., Baudhuin J., LeMaoult J., Sousa S., Doliger C., Carosella E. D., Favier B., Human melanoma cell secreting human leukocyte antigen-G5 inhibit natural killer cell cytotoxicity by impairing lytic granules polarization toward target cell. Human Immunology 2009 70 12 1000 1005 2-s2.0-70350733501 10.1016/j.humimm.2009.07.019
125. Konjevic G., Mirjacic Martinovic K., Vuletic A., Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients. Clinical and Experimental Metastasis 2007 24 1 1 11 (Pubitemid 46569334)
126. Umansky V., Sevko A., Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation. Cancer Immunology, Immunotherapy 2012 61 2 275 282
127. Guilloux Y., Viret C., Gervois N., Le Drean E., Pandolfino M. C., Diez E., Jotereau F., Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. European Journal of Immunology 1994 24 9 1966 1973 2-s2.0-0028025028
128. Simon A. K., Jones E., Richards H., Wright K., Betts G., Godkin A., Screaton G., Gallimore A., Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity. European Journal of Immunology 2007 37 3 758 767 2-s2.0-34147129582 10.1002/eji.200636593 (Pubitemid 46916942)
129. Viguier M., Lemaître F., Verola O., Cho M. S., Gorochov G., Dubertret L., Bachelez H., Kourilsky P., Ferradini L., Foxp3 expressing CD4+CD25high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. Journal of Immunology 2004 173 2 1444 1453 2-s2.0-3142737258 (Pubitemid 38924326)
130. McCarter M. D., Baumgartner J., Escobar G. A., Richter D., Lewis K., Robinson W., Wilson C., Palmer B. E., Gonzalez R., Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Annals of Surgical Oncology 2007 14 10 2854 2860 2-s2.0-34648832062 10.1245/s10434-007-9488-3 (Pubitemid 47460650)
131. Tsuji K., Hamada T., Uenaka A., Wada H., Sato E., Isobe M., Asagoe K., Yamasaki O., Shiku H., Ritter G., Murphy R., Hoffman E. W., Old L. J., Nakayama E., Iwatsuki K., Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient. Cancer Immunology, Immunotherapy 2008 57 10 1429 1437 2-s2.0-48149088825 10.1007/s00262-008-0478-5
132. Nicholaou T., Ebert L. M., Davis I. D., McArthur G. A., Jackson H., Dimopoulos N., Tan B., Maraskovsky E., Miloradovic L., Hopkins W., Pan L., Venhaus R., Hoffman E. W., Chen W., Cebon J., Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clinical Cancer Research 2009 15 6 2166 2173 2-s2.0-63549100184 10.1158/1078-0432.CCR-08-2484
133. Zhao F., Falk C., Osen W., Kato M., Schadendorf D., Umansky V., Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clinical Cancer Research 2009 15 13 4382 4390 2-s2.0-67650354587 10.1158/1078-0432.CCR-09-0399
134. Munn D. H., Sharma M. D., Hou D., Baban B., Lee J. R., Antonia S. J., Messina J. L., Chandler P., Koni P. A., Mellor A. L., Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. The Journal of Clinical Investigation 2004 114 4 599 2-s2.0-9644284712 10.1172/JCI200421583E1 (Pubitemid 39572112)
135. Charles J., Di Domizio J., Salameire D., Bendriss-Vermare N., Aspord C., Muhammad R., Lefebvre C., Plumas J., Leccia M. T., Chaperot L., Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor. Journal of Investigative Dermatology 2010 130 6 1646 1656 2-s2.0-77952428692 10.1038/jid.2010.24